International Conference on Oncology and Carcinogensis - (ICOC-26)


13th - 14th November, 2026 | Richmond Hill, Canada

Multi-format (In-person/Virtual)

Registration Options

Explore conference registration categories designed for every mode of participation.

Important Dates

Pre-registration Deadline

14th October, 2026

Paper Submission Deadline

19th October, 2026

Last Date Of Registration

29th October, 2026

Date Of Conference

13th - 14th November, 2026

Downloads

Conference Session Tracks

SDG Wheel

Aligned with

UN Sustainable Development Goals

This conference contributes to global sustainability by aligning its research discussions and academic sessions with key United Nations Sustainable Development Goals. It fosters knowledge exchange, innovation, and collaborative engagement.

SDG 2 SDG 2 — Zero Hunger
SDG 3 SDG 3 — Good Health and Well-being
SDG 4 SDG 4 — Quality Education
SDG 9 SDG 9 — Industry, Innovation and Infrastructure
SDG 10 SDG 10 — Reduced Inequalities
SDG 16 SDG 16 — Peace, Justice and Strong Institutions
Explore

All Session Tracks

Track 01
Advancements in Oncology Research

This track focuses on the latest breakthroughs in oncology, including novel therapeutic strategies and innovative research methodologies. Participants will explore the implications of these advancements for patient care and treatment outcomes.

Track 02
Carcinogenesis Mechanisms and Pathways

This session will delve into the molecular and cellular mechanisms underlying carcinogenesis, highlighting key signaling pathways and genetic factors. Discussions will include the role of environmental and lifestyle factors in cancer development.

Track 03
Clinical Trials and Therapeutic Innovations

This track will examine the design, implementation, and outcomes of clinical trials in oncology. Emphasis will be placed on emerging therapies and their potential to reshape cancer treatment paradigms.

Track 04
Immunotherapy in Cancer Treatment

Participants will investigate the role of immunotherapy in oncology, focusing on the latest developments in immune checkpoint inhibitors and CAR-T cell therapy. The session will address challenges and future directions in harnessing the immune system to combat cancer.

Track 05
Nutrition and Cancer Prevention

This track will explore the relationship between nutrition and cancer risk, emphasizing dietary interventions that may reduce incidence. Discussions will include the role of specific nutrients and dietary patterns in cancer prevention.

Track 06
Pediatric Oncology: Challenges and Innovations

This session will focus on the unique challenges faced in pediatric oncology, including diagnosis, treatment, and long-term survivorship. Innovative approaches in research and clinical practice will be highlighted.

Track 07
Pharmacology in Oncology: Drug Development

This track will cover the pharmacological aspects of drug development for cancer treatment, including pharmacokinetics and pharmacodynamics. Participants will discuss the challenges of drug resistance and strategies to overcome it.

Track 08
Public Health Strategies in Cancer Control

This session will address public health initiatives aimed at cancer prevention and control, focusing on screening, education, and community engagement. The role of policy in shaping effective cancer control strategies will also be discussed.

Track 09
Integrative Approaches in Cancer Care

This track will explore the integration of complementary and alternative medicine in oncology, examining evidence-based practices and patient outcomes. Discussions will focus on holistic approaches to cancer treatment and management.

Track 10
Emerging Technologies in Oncology

Participants will investigate the impact of emerging technologies, such as artificial intelligence and genomics, on oncology research and clinical practice. The session will highlight how these technologies can enhance diagnosis and treatment.

Track 11
Ethical Considerations in Oncology Research

This track will address the ethical challenges associated with oncology research, including informed consent, patient autonomy, and equitable access to treatment. Participants will engage in discussions on best practices for ethical conduct in clinical trials.